查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433663

眼科藥品市場規模、佔有率、趨勢分析報告：依藥物類別、疾病、劑型類型、給藥途徑、產品類型、產品、地區、細分市場預測，2024-2030年

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Product, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

眼科藥品市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球眼科藥品市場規模將達到655.5億美元，2023年至2030年複合年成長率為7.80%。

人們對眼疾的認知不斷提高，眼科藥物需求激增，是推動市場成長的因素。此外，老齡化黃斑部病變、白內障、乾眼症、糖尿病視網膜病變和青光眼等眼科疾病的日益普及預計將推動對眼科藥物的需求。

根據BrightFocus基金會預計，2021年將有超過300萬美國患有青光眼，其中超過270萬名患者將患有最常見的青光眼類型—開放性青光眼。此外，美國有 330 萬人失明或視力低下。青光眼和失明的主要危險因子包括年齡較大、家族病史、角膜薄和高眼壓。這為眼科藥物創造了廣泛的人口基礎，確保了良好的成長。

此外，眼科藥品和藥物輸送公司正在接受財政援助，以促進開發新藥技術進步的研究和開發，這可能會推動市場成長。例如，2020 年 6 月，Re-Vana Therapeutics 從 Qubis、ExSight Ventures, LLC、Clarendon Fund Managers、Visionary Ventures 和 Techstart Ventures LLP 獲得了 325 萬美元的 Pre-A 輪融資。這筆資金籌措將加速 Li-Vana Therapeutics 的 EyeLief 和 OcuLief生物分解性技術的開發，這些技術預計將用於輸送小分子和生技藥品。

此外，老年人口的增加是眼科藥物市場成長的主要驅動力。據 Safe Eyes America 稱，眼疾最常見的危險因子是年齡較大、家族病史、糖尿病和高血壓。例如，根據美國健康排名2021年高級報告，超過5,400萬65歲及以上的成年人居住在美國，佔總人口的16.5%。根據黃斑部病變研究，AMD 是 60 歲以上美國失明的第一大原因。

眼科產品的持續監管核准可能會支持市場成長。例如，參天製藥株式會社於2022年6月宣布，其治療乾眼症的Diquas LX眼藥水已在日本獲得生產和銷售核准。該眼藥水是一種改良的配方，可減少給藥頻率並提高患者的依從性。

眼科藥品市場報告亮點

  • 由於需求增加和副作用較少，抗 VEGF 藥物在 2022 年佔據最大佔有率。
  • 由於老齡化黃斑部病變和糖尿病性視網膜病變的盛行率不斷上升，視網膜病變將在 2022 年佔據最大的市場佔有率。
  • 由於局部給藥途徑將藥物遞送至局部部位的優勢和易用性等因素，局部給藥途徑在 2022 年佔據市場主導地位。
  • 由於眼藥水需求不斷成長、患者依從性高以及 OTC 產品易於獲得，預計到 2022 年，眼藥水細分市場將佔據最大的市場佔有率。
  • 由於醫療基礎設施的進步、對眼科產品的需求不斷增加以及患者人數眾多，預計亞太地區在預測期內將出現最快的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章眼科藥品市場：變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 眼科藥品市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 管道分析
    • 專利到期分析

第4章眼科藥物市場：藥物類別的估計與趨勢分析

  • 2023年及2030年藥品類別市場佔有率
  • 細分儀表板
  • 按藥物類別分類的全球眼科藥物市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章眼科藥品市場：疾病估計與趨勢分析

  • 2023年及2030年疾病市場佔有率
  • 細分儀表板
  • 全球眼科藥物市場（依疾病分類）展望
  • 2018年至2030年市場規模、預測與趨勢分析

第6章 眼科用藥市場：給藥途徑預估及趨勢分析

  • 2023 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 按給藥途徑分類的全球眼科藥物市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第7章眼科藥品市場：劑型類型的估計與趨勢分析

  • 劑型類型市場佔有率，2023 年和 2030 年
  • 細分儀表板
  • 按劑型類型分類的全球眼科藥品市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第8章眼科藥品市場：產品類型估算及趨勢分析

  • 2023 年及 2030 年產品類型市場佔有率
  • 細分儀表板
  • 按產品類型分類的全球眼科藥品市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第9章眼科藥品市場：產品評估與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的全球眼科藥品市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第10章眼科藥品市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Pfizer Inc.
    • Alcon
    • Novartis AG
    • Bausch Health Companies Inc.
    • Merck &Co., Inc.
    • Regeneron Pharmaceuticals Inc.
    • Allergan（AbbVie Inc）
    • Bayer AG
    • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
    • Nicox
    • Coherus BioSciences
Product Code: GVR-2-68038-010-1

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 65.55 billion by 2030, garnering a CAGR of 7.80% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

  • Anti-VEGF agents segment held the largest share in 2022 owing to their rising demand and lesser adverse effects
  • Retinal disorders held the largest market share in 2022 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
  • The topical route of administration dominated the market in 2022 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
  • The eye drops segment is expected to hold the largest share in 2022 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
  • Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Disease
    • 1.2.3. Route of Administration
    • 1.2.4. Dosage Type
    • 1.2.5. Product Type
    • 1.2.6. Product
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class and disease outlook
    • 2.2.2. Route of administration and dosage type outlook
    • 2.2.3. Product type and product outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing disease prevalence
      • 3.2.1.2. Strong developmental pipeline
      • 3.2.1.3. Advancement in drug delivery
      • 3.2.1.4. Promising investment scenario
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of blockbuster drugs
  • 3.3. Ophthalmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
    • 3.3.5. Patent Expiry Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Ophthalmic Drugs Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Anti-allergy
      • 4.4.1.1. Anti-allergy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Anti-VEGF Agents
      • 4.4.2.1. Anti-VEGF agents market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Anti-inflammatory
      • 4.4.3.1. Anti-inflammatory market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.2. Non-steroidal drugs
      • 4.4.3.2.1. Non-steroidal drugs market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.3. Steroids
      • 4.4.3.3.1. Steroids market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Anti- glaucoma
      • 4.4.4.1. Anti- glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Gene and Cell Therapy
      • 4.4.5.1. Gene and cell therapy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.6. Others
      • 4.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Ophthalmic Drugs Market by Disease Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Dry Eye
      • 5.4.1.1. Dry eye market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Allergies
      • 5.4.2.1. Allergies market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Glaucoma
      • 5.4.3.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Infection
      • 5.4.4.1. Infection market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Retinal Disorders
      • 5.4.5.1. Retinal disorders market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.2. Macular Degeneration
      • 5.4.5.2.1. Macular degeneration market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.3. Diabetic Retinopathy
      • 5.4.5.3.1. Diabetic retinopathy market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.4. Others
      • 5.4.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.6. Uveitis
      • 5.4.6.1. Uveitis market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Ophthalmic Drugs Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Topical
      • 6.4.1.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Local Ocular
      • 6.4.2.1. Local ocular market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.2. Subconjunctival
      • 6.4.2.2.1. Subconjunctival market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.3. Intravitreal
      • 6.4.2.3.1. Intravitreal market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.4. Retrobulbar
      • 6.4.2.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.5. Intracameral
      • 6.4.2.5.1. Intracameral market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Systemic
      • 6.4.3.1. Systemic market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

  • 7.1. Dosage Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Ophthalmic Drugs Market by Dosage Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Gels
      • 7.4.1.1. Gels market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Eye Solutions and Suspensions
      • 7.4.2.1. Eye solutions and suspensions market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. Capsules and Tablets
      • 7.4.3.1. Capsules and tablets market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.4. Eye Drops
      • 7.4.4.1. Eye drops market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.5. Ointments
      • 7.4.5.1. Ointments market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

  • 8.1. Product Type Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Ophthalmic Drugs Market by Product Type Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. OTC
      • 8.4.1.1. OTC market estimates and forecasts 2018 to 2030 (USD Billion)
    • 8.4.2. Prescription Drugs
      • 8.4.2.1. Prescription drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 9. Ophthalmic Drugs Market: Product Estimates & Trend Analysis

  • 9.1. Product Market Share, 2023 & 2030
  • 9.2. Segment Dashboard
  • 9.3. Global Ophthalmic Drugs Market by Product Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. Branded Drugs
      • 9.4.1.1. Branded drugs market estimates and forecasts 2018 to 2030 (USD Billion)
    • 9.4.2. Generic Drugs
      • 9.4.2.1. Generic drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2023 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. U.S.
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/ reimbursement structure
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.5.2. Canada
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/ reimbursement structure
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6. Europe
    • 10.6.1. UK
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/ reimbursement structure
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.2. Germany
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/ reimbursement structure
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.3. France
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework/ reimbursement structure
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.4. Italy
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework/ reimbursement structure
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.5. Spain
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework/ reimbursement structure
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.6. Norway
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework/ reimbursement structure
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.7. Sweden
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework/ reimbursement structure
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.8. Denmark
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework/ reimbursement structure
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7. Asia Pacific
    • 10.7.1. Japan
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/ reimbursement structure
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.2. China
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/ reimbursement structure
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.3. India
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/ reimbursement structure
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.4. Australia
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/ reimbursement structure
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.5. South Korea
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework/ reimbursement structure
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.6. Thailand
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework/ reimbursement structure
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.8. Latin America
    • 10.8.1. Brazil
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework/ reimbursement structure
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.8.2. Mexico
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework/ reimbursement structure
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.8.3. Argentina
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework/ reimbursement structure
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.9. MEA
    • 10.9.1. South Africa
      • 10.9.1.1. Key country dynamics
      • 10.9.1.2. Regulatory framework/ reimbursement structure
      • 10.9.1.3. Competitive scenario
      • 10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.2. Saudi Arabia
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework/ reimbursement structure
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.3. UAE
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework/ reimbursement structure
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.4. Kuwait
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework/ reimbursement structure
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2023
    • 11.3.4. Pfizer Inc.
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Product benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Alcon
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Product benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Novartis AG
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Product benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Bausch Health Companies Inc.
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Product benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Merck & Co., Inc.
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Product benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Regeneron Pharmaceuticals Inc.
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Product benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. Allergan (AbbVie Inc)
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Product benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. Bayer AG
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Product benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Product benchmarking
      • 11.3.12.4. Strategic initiatives
    • 11.3.13. Nicox
      • 11.3.13.1. Company overview
      • 11.3.13.2. Financial performance
      • 11.3.13.3. Product benchmarking
      • 11.3.13.4. Strategic initiatives
    • 11.3.14. Coherus BioSciences
      • 11.3.14.1. Company overview
      • 11.3.14.2. Financial performance
      • 11.3.14.3. Product benchmarking
      • 11.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 3 North America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 4 North America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 5 North America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 6 North America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 7 North America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 8 North America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 9 U.S. ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 10 U.S. ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 11 U.S. ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 12 U.S. ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 13 U.S. ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 14 U.S. ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 15 Canada ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 16 Canada ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 17 Canada ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 18 Canada ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 19 Canada ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 20 Canada ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 21 Europe ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 22 Europe ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 23 Europe ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 24 Europe ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 25 Europe ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 26 Europe ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 27 Europe ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 28 Germany ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 29 Germany ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 30 Germany ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 31 Germany ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 32 Germany ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 33 Germany ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 34 UK ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 35 UK ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 36 UK ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 37 UK ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 38 UK ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 39 UK ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 40 France ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 41 France ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 42 France ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 43 France ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 44 France ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 45 France ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 46 Italy ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 47 Italy ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 48 Italy ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 49 Italy ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 50 Italy ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 51 Italy ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 52 Spain ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 53 Spain ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 54 Spain ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 55 Spain ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 56 Spain ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 57 Spain ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 58 Denmark ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 59 Denmark ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 60 Denmark ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 61 Denmark ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 62 Denmark ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 63 Denmark ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 64 Sweden ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 65 Sweden ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 66 Sweden ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 67 Sweden ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 68 Sweden ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 69 Sweden ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 70 Norway ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 71 Norway ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 72 Norway ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 73 Norway ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 74 Norway ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 75 Norway ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 77 Asia Pacific ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 78 Asia Pacific ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 79 Aisa Pacific ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 80 Aisa Pacific ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 81 Aisa Pacific ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 82 Aisa Pacific ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 83 China ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 84 China ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 85 China ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 86 China ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 87 China ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 88 China ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 89 Japan ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 90 Japan ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 91 Japan ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 92 Japan ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 93 Japan ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 94 Japan ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 95 India ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 96 India ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 97 India ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 98 India ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 99 India ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 100 India ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 101 South Korea ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 102 South Korea ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 103 South Korea ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 104 South Korea ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 105 South Korea ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 106 South Korea ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 107 Australia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 108 Australia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 109 Australia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 110 Australia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 111 Australia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 112 Australia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 113 Thailand ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 114 Thailand ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 115 Thailand ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 116 Thailand ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 117 Thailand ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 118 Thailand ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 119 Latin America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 120 Latin America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 121 Latin America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 122 Latin America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 123 Latin America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 124 Latin America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 125 Latin America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 126 Brazil ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 127 Brazil ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 128 Brazil ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 129 Brazil ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 130 Brazil ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 131 Brazil ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 132 Mexico ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 133 Mexico ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 134 Mexico ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 135 Mexico ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 136 Mexico ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 137 Mexico ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 138 Argentina ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 139 Argentina ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 140 Argentina ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 141 Argentina ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 142 Argentina ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 143 Argentina ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 144 MEA ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 145 MEA ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 146 MEA ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 147 MEA ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 148 MEA ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 149 MEA ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 150 MEA ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 151 South Africa ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 152 South Africa ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 153 South Africa ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 154 South Africa ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 155 South Africa ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 156 South Africa ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 157 Saudi Arabia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 158 Saudi Arabia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 159 Saudi Arabia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 160 Saudi Arabia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 161 Saudi Arabia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 162 Saudi Arabia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 163 UAE ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 164 UAE ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 165 UAE ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 166 UAE ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 167 UAE ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 168 UAE ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 169 Kuwait ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 170 Kuwait ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 171 Kuwait ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 172 Kuwait ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 173 Kuwait ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 174 Kuwait ophthalmic drugs market, by product 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Ophthalmic drugs market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Ophthalmic drugs market driver impact
  • Fig. 20 Ophthalmic drugs market restraint impact
  • Fig. 21 Ophthalmic drugs market strategic initiatives analysis
  • Fig. 22 Ophthalmic drugs market: Drug class movement analysis
  • Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
  • Fig. 24 Anti-allergy market estimates and forecast, 2018 - 2030
  • Fig. 25 Anti-VEGF agents estimates and forecast, 2018 - 2030
  • Fig. 26 Anti-inflammatory market estimates and forecast, 2018 - 2030
  • Fig. 27 Anti-glaucoma estimates and forecast, 2018 - 2030
  • Fig. 28 Gene and cell therapy market estimates and forecast, 2018 - 2030
  • Fig. 29 Others estimates and forecast, 2018 - 2030
  • Fig. 30 Ophthalmic drugs market: Disease movement analysis
  • Fig. 31 Ophthalmic drugs market: Disease outlook and key takeaways
  • Fig. 32 Dry eye market estimates and forecast, 2018 - 2030
  • Fig. 33 Allergies estimates and forecast, 2018 - 2030
  • Fig. 34 Glaucoma market estimates and forecast, 2018 - 2030
  • Fig. 35 Infection estimates and forecast, 2018 - 2030
  • Fig. 36 Retinal disorders market estimates and forecast, 2018 - 2030
  • Fig. 37 Uveitis estimates and forecast, 2018 - 2030
  • Fig. 38 Others estimates and forecast, 2018 - 2030
  • Fig. 39 Ophthalmic drugs market: Route of administration movement analysis
  • Fig. 40 Ophthalmic drugs market: Route of administration outlook and key takeaways
  • Fig. 41 Topical market estimates and forecast, 2018 - 2030
  • Fig. 42 Local ocular estimates and forecast, 2018 - 2030
  • Fig. 43 Systemic market estimates and forecast, 2018 - 2030
  • Fig. 44 Ophthalmic drugs market: Dosage type movement analysis
  • Fig. 45 Ophthalmic drugs market: Dosage type outlook and key takeaways
  • Fig. 46 Gels market estimates and forecast, 2018 - 2030
  • Fig. 47 Eye solutions and suspensions estimates and forecast, 2018 - 2030
  • Fig. 48 Capsules and tablets market estimates and forecast, 2018 - 2030
  • Fig. 49 Eye drops estimates and forecast, 2018 - 2030
  • Fig. 50 Ointments market estimates and forecast, 2018 - 2030
  • Fig. 51 Ophthalmic drugs market: Product type movement analysis
  • Fig. 52 Ophthalmic drugs market: Product type outlook and key takeaways
  • Fig. 53 OTC market estimates and forecast, 2018 - 2030
  • Fig. 54 Prescription drugs estimates and forecast, 2018 - 2030
  • Fig. 55 Ophthalmic drugs market: Product movement Analysis
  • Fig. 56 Ophthalmic drugs market: Product outlook and key takeaways
  • Fig. 57 Branded drugs market estimates and forecasts, 2018 - 2030
  • Fig. 58 Generic drugs market estimates and forecasts,2018 - 2030
  • Fig. 59 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 60 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 61 Global ophthalmic drugs market share and leading players
  • Fig. 62 North America market share and leading players
  • Fig. 63 Europe market share and leading players
  • Fig. 64 Asia Pacific market share and leading players
  • Fig. 65 Latin America market share and leading players
  • Fig. 66 Middle East & Africa market share and leading players
  • Fig. 67 North America: SWOT
  • Fig. 68 Europe SWOT
  • Fig. 69 Asia Pacific SWOT
  • Fig. 70 Latin America SWOT
  • Fig. 71 MEA SWOT
  • Fig. 72 North America, by country
  • Fig. 73 North America
  • Fig. 74 North America market estimates and forecasts, 2018 - 2030
  • Fig. 75 U.S. key country dynamics
  • Fig. 76 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 77 Canada key country dynamics
  • Fig. 78 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 79 Europe
  • Fig. 80 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 81 UK key country dynamics
  • Fig. 82 UK market estimates and forecasts, 2018 - 2030
  • Fig. 83 Germany key country dynamics
  • Fig. 84 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 85 France key country dynamics
  • Fig. 86 France market estimates and forecasts, 2018 - 2030
  • Fig. 87 Italy key country dynamics
  • Fig. 88 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 89 Spain key country dynamics
  • Fig. 90 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 91 Denmark key country dynamics
  • Fig. 92 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 93 Sweden key country dynamics
  • Fig. 94 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 95 Norway key country dynamics
  • Fig. 96 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 97 Asia Pacific
  • Fig. 98 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 99 China key country dynamics
  • Fig. 100 China market estimates and forecasts, 2018 - 2030
  • Fig. 101 Japan key country dynamics
  • Fig. 102 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 103 India key country dynamics
  • Fig. 104 India market estimates and forecasts, 2018 - 2030
  • Fig. 105 Thailand key country dynamics
  • Fig. 106 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 107 South Korea key country dynamics
  • Fig. 108 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 109 Australia key country dynamics
  • Fig. 110 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 111 Latin America
  • Fig. 112 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 113 Brazil key country dynamics
  • Fig. 114 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 115 Mexico key country dynamics
  • Fig. 116 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 117 Argentina key country dynamics
  • Fig. 118 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 119 Middle East and Africa
  • Fig. 120 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 121 South Africa key country dynamics
  • Fig. 122 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 123 Saudi Arabia key country dynamics
  • Fig. 124 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 125 UAE key country dynamics
  • Fig. 126 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 127 Kuwait key country dynamics
  • Fig. 128 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 129 Market share of key market players- Ophthalmic drugs market